A method for treating demyelinating diseases in a patient in need thereof
by treatment with an effective amount of a PPAR delta agonist is
disclosed. Demyelinating diseases that may be effectively treated by this
method include but are not limited to multiple sclerosis,
Charcot-Marie-Tooth disease, Pelizaeus-Merzbacher disease,
encephalomyelitis, neuromyelitis optica, adrenoleukodystrophy,
Guillian-Barre syndrome and disorders in which myelin forming glial cells
are damaged including spinal cord injuries, neuropathies and nerve
injury.